AlphaFold predicted structure
IRS4 · O14654

Mean pLDDT
48.2/ 100
Very low
1,257 residues
Confidence breakdown
- Very high(≥ 90)10%
- Confident(70–90)9%
- Low(50–70)7%
- Very low(< 50)73%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
insulin receptor substrate 4
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
Congenital hypothyroidism
X-LINKED: hemizygous mutation in males, biallelic mutations in femalesneurodegenerative disease
hypothyroidism, congenital, nongoitrous, 9
melanoma
central congenital hypothyroidism
lung adenocarcinoma
skin basal cell carcinoma
brain glioblastoma
endometrial endometrioid adenocarcinoma
colon adenocarcinoma
colorectal adenocarcinoma
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Insulin receptor substrate 4
Acts as an interface between multiple growth factor receptors possessing tyrosine kinase activity, such as insulin receptor, IGF1R and FGFR1, and a complex network of intracellular signaling molecules containing SH2 domains. Involved in the IGF1R mitogenic signaling pathway. Promotes the AKT1 signaling pathway and BAD phosphorylation during insulin stimulation without activation of RPS6KB1 or the inhibition of apoptosis. Interaction with GRB2 enhances insulin-stimulated mitogen-activated protein kinase activity. May be involved in nonreceptor tyrosine kinase signaling in myoblasts. Plays a pivotal role in the proliferation/differentiation of hepatoblastoma cell through EPHB2 activation upon IGF1 stimulation. May play a role in the signal transduction in response to insulin and to a lesser extent in response to IL4 and GH on mitogenesis. Plays a role in growth, reproduction and glucose homeostasis. May act as negative regulators of the IGF1 signaling pathway by suppressing the function of IRS1 and IRS2
IRS4 · O14654

Mean pLDDT
48.2/ 100
Very low
1,257 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0